Prices delayed by at least 15 minutes | Print
Madrigal Pharmaceuticals (MDGL)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Address
200 Barr Harbor Drive
Suite 400, Four Tower Bridge
West Conshohocken
PA
USA
19428
Telephone
+1 781 5417250
Forecast key dates
Name | Key Date |
---|---|
Madrigal Pharmaceuticals Inc First Quarter Earnings Conference Call for 2025 | 2025-05-07T08:00:00 |
Madrigal Pharmaceuticals Inc First Quarter Earnings Results for 2025 | 2025-05-07T00:00:00 |
Madrigal Pharmaceuticals Inc Fourth Quarter Earnings Results for 2024 | 2025-02-28T00:00:00 |
Madrigal Pharmaceuticals Inc Annual Report for 2024 | 2025-02-28T00:00:00 |
Madrigal Pharmaceuticals Inc Third Quarter Earnings Results for 2024 | 2024-11-06T00:00:00 |
Madrigal Pharmaceuticals Inc Second Quarter Earnings Results for 2024 | 2024-08-08T00:00:00 |
Madrigal Pharmaceuticals Inc Annual General Meeting for 2024 | 2024-06-14T09:00:00 |
Madrigal Pharmaceuticals Inc First Quarter Earnings Conference Call for 2024 | 2024-05-07T08:00:00 |
Madrigal Pharmaceuticals Inc First Quarter Earnings Result for 2024 | 2024-05-07T00:00:00 |
Previous key dates
Name | Key Date |
---|---|
Madrigal Pharmaceuticals Inc First Quarter Earnings Conference Call for 2024 | 2024-05-07T08:00:00 |
Madrigal Pharmaceuticals Inc First Quarter Earnings Result for 2024 | 2024-05-07T00:00:00 |
Madrigal to discuss the accelerated approval of Rezdiffra 2024 | 2024-03-14T17:15:00 |
Madrigal Pharmaceuticals Inc Fourth Quarter Earnings Results for 2023 | 2024-02-28T00:00:00 |
Madrigal Pharmaceuticals Inc Annual Report for 2023 | 2024-02-28T00:00:00 |
Madrigal Pharmaceuticals Inc Third Quarter Earnings Results for 2023 | 2023-11-06T00:00:00 |
Madrigal Pharmaceuticals Inc Second Quarter Earnings Results for 2023 | 2023-08-08T00:00:00 |
Madrigal Pharmaceuticals Inc Annual General Meeting for 2023 | 2023-06-15T09:00:00 |
Madrigal Pharmaceuticals Inc First Quarter Earnings Results for 2023 | 2023-05-09T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.